Discrete Proton Arc Therapy achieves its first global clinical use, improving dose precision and reducing side effects in head and neck cancer treatment.
Discrete Proton Arc Therapy: First Worldwide Clinical Use for Head and Neck Cancer
Cancer treatment continues to evolve as precision technologies improve. Recently, Discrete Proton Arc Therapy (PAT) reached a historic milestone in radiation oncology. In October 2024, clinicians completed the first worldwide clinical implementation of this technique for head and neck cancer patients.
Importantly, this advancement shows that discrete proton arc therapy can improve dose control while maintaining clinical efficiency. As a result, patients benefit from safer treatments without added workflow complexity.
Who Developed Discrete Proton Arc Therapy?
Francesco Fracchiolla, Erik Engwall, Victor Mikhalev, Marco Cianchetti, Irene Giacomelli, Benedetta Siniscalchi, Johan Sundström, Otte Marthin, Viktor Wase, Mattia Bertolini, Roberto Righetto, Annalisa Trianni, Frank Lohr, Stefano Lorentini conducted this research and published it under the title “A COMPREHENSIVE CLINICAL COMMISSIONING AND FIRST CLINICAL WORLDWIDE IMPLEMENTATION OF HEAD AND NECK DISCRETE PROTON ARC TREATMENTS” in December 2025.
ENTECH STEM Magazine has included this research in its list of Top 10 Physics Discoveries and Innovation of 2025.
This innovation emerged from a collaboration between clinical experts and industry specialists. The lead clinical work took place at the Trento Proton Therapy Center in Italy. Meanwhile, treatment planning development came from RaySearch Laboratories in Sweden.
What Is Discrete Proton Arc Therapy (PAT)?
Understanding the Core Innovation
Discrete proton arc therapy is an advanced form of proton beam therapy. Instead of using continuous arcs, it delivers proton beams from multiple fixed angles arranged in an arc-like pattern. Each angle includes several energy layers, allowing precise dose shaping.
Because PAT uses discrete beam positions, it improves dose conformity around tumors. At the same time, it limits radiation exposure to nearby healthy organs. Therefore, treatment accuracy increases without compromising safety.
Moreover, Discrete Proton Arc Therapy builds upon robust optimization methods already used in clinics. It was directly compared with multi-field optimization (MFO), which represents the current standard of care.
Clinical Performance of Discrete Proton Arc Therapy
Patient Study and Planning Approach
To evaluate discrete proton arc therapy, researchers studied 10 head and neck cancer patients. Each patient received a median prescribed dose of 70 GyRBE. Both PAT and MFO plans were created using standard clinical workflows.
PAT plans used 30 beam directions with 360 energy layers. Comparisons focused on dose quality, robustness, and treatment delivery time. Consequently, the study ensured a fair and clinically relevant evaluation.
Dose Quality and Organ Protection
The results showed no statistically significant differences in target coverage between PAT and MFO. Key metrics such as D95 and D98 remained consistent across all patients. Therefore, tumor control quality was maintained.
However, discrete proton arc therapy provided a clear advantage for organ protection. Mean doses to secondary organs at risk, including the brainstem, were significantly reduced. This reduction lowers the risk of long-term complications.
Additionally, LETd distributions within brain structures showed no significant differences. As a result, biological dose effects remained comparable between treatment methods.
Patient Outcome Indicators
The study also evaluated normal tissue complication probability (NTCP). Endpoints included xerostomia, swallowing dysfunction, tube feeding risk, and sticky saliva.
Discrete Proton Arc Therapy reduced the median NTCP for xerostomia by 8.5%. While other reductions were not statistically significant, no outcome worsened with PAT. Thus, patient safety remained intact.
Replanning probability was also assessed. Importantly, PAT required a similar replanning frequency as MFO. Therefore, existing clinical monitoring workflows remain unchanged.
Practical Uses of Discrete Proton Arc Therapy
Treatment Time and Clinical Efficiency
Treatment delivery time is crucial in busy cancer centers. In this study, MFO treatments averaged 31 minutes. Meanwhile, PAT with 30 directions required 36 minutes.
However, when reduced to20 beam directions, discrete proton arc therapy achieved a delivery time of 25 minutes. As a result, optimized PAT configurations can be even faster than current treatments.
This flexibility allows clinics to tailor treatment parameters while maintaining efficiency and patient comfort.
Real-World Benefits for Patients and Clinics
Discrete proton arc therapy significantly reduces radiation exposure outside tumor targets. This benefit is especially important for head and neck cancer, where organs controlling speech, swallowing, and breathing are nearby.
Because PAT integrates smoothly into existing workflows, clinics can adopt it without major operational changes. Consequently, patients receive safer treatments while clinicians maintain efficiency.
Commercial Readiness and Future Outlook
Current Clinical Status
Unlike many experimental techniques, Discrete Proton Arc Therapy is already clinically deployed. The first treatments occurred in October 2024, confirming full readiness for real-world use.
As a result, PAT is available for immediate clinical adoption in head and neck cancer treatment.
Future Expansion Potential
Looking ahead, discrete proton arc therapy may expand to other cancer sites, including thoracic and pelvic tumors. Ongoing research will guide these applications.
Meanwhile, continued advances in treatment planning software may further reduce delivery times and improve optimization.
Research Areas and Career Paths for Students
Students interested in Additionally, to stay updated with the latest developments in STEM research, visit ENTECH Online. Basically, this is our digital magazine for science, technology, engineering, and mathematics. Further, at ENTECH Online, you’ll find a wealth of information. can pursue careers in:
- Medical physics, focusing on proton beam modeling and robust optimization
- Radiation oncology, studying patient outcomes and toxicity reduction
- Software and systems engineering, developing treatment planning algorithms
Hospitals, research centers, and technology companies actively seek these skills.
Why Discrete Proton Arc Therapy Matters
Discrete Proton Arc Therapy represents a major advancement in cancer care. It improves dose precision, protects healthy tissue, and preserves clinical efficiency.
Most importantly, it demonstrates how innovation can enhance patient outcomes without increasing complexity. As proton therapy evolves, Discrete Proton Arc Therapy sets a new standard for precision radiation treatment.
Additionally, to stay updated with the latest developments in STEM research, visit ENTECH Online. Basically, this is our digital magazine for science, technology, engineering, and mathematics. Further, at ENTECH Online, you’ll find a wealth of information.
Reference:
- Engwall, E., Cianchetti, M., Giacomelli, I., Siniscalchi, B., Sundström, J., Marthin, O., Bertolini, M., & Lorentini, S. (2025). A COMPREHENSIVE CLINICAL COMMISSIONING AND FIRST CLINICAL WORLDWIDE IMPLEMENTATION OF HEAD AND NECK DISCRETE PROTON ARC TREATMENTS. International Journal of Particle Therapy, 17, 100769. https://doi.org/10.1016/j.ijpt.2025.100769
- Author
- Latest Posts
I’m a web developer and science writer with a Master’s degree in Computer Applications (MCA) from Pune University.
I work in tech, building websites and staying updated with the latest developments. I also love writing about physics, chemistry, technology, robotics, mathematics, and breakthrough innovations. My passion is breaking down complex scientific topics into simple, easy-to-understand stories.
My goal is to help everyone stay informed about the exciting changes happening in science and technology. I believe understanding science shouldn’t be complicated—it should be accessible to all.
